Telehealth Services for Mental Health Care: A Secret Shopper Study

By HEOR Staff Writer

February 22, 2024

Telehealth Services for Mental Health Care

Introduction:

There have been major shifts in healthcare delivery due to the recent pandemic, with telehealth being one area that has seen the most impact. In the United States, the use of telehealth services for mental health care has seen a remarkable increase, fuelled by changes in federal and state policies related to financial reimbursement of these services.

The Rise of Telehealth in Mental Health Care:

Particularly in the midst of the epidemic, telehealth has emerged as an indispensable instrument for the delivery of mental health treatments. According to studies, the overall volume of services for mental health issues has remained consistent, despite constraints on in-person care. This can be partly due to the rise in the number of telehealth appointments. On the other hand, the availability of these telehealth services and the makeup of these services are still substantially unexplored.

The Secret Shopper Approach:

A ‘Secret Shopper’ strategy was utilised in a recent study in order to gain an understanding of the present landscape of telehealth services for mental health care professionals. In this approach, researchers make contact with establishments while posing as potential customers in order to inquire about the availability of services. By taking this method, a clear and up-to-date image of the layout of services across the United States is provided.

Findings and Discussions:

The survey revealed that approximately one in five facilities did not respond despite multiple attempts. Among those successfully contacted, most were accepting new clients and offering telehealth services. However, the availability of telehealth services varied across states, and there was heterogeneity in the types of clinical services offered via telehealth.

Figure 1. State-Specific Median Wait Times to Next Available Telehealth Appointment
at Surveyed Mental Health Treatment Facilities

The survey also found that the median wait time for a telehealth appointment was over two weeks, with significant geographic variation. Interestingly, private facilities were nearly twice as likely to offer telehealth services compared with public facilities.

Implications and Future Directions:

These findings underscore potential heterogeneity in the availability of treatment from specialty practitioners in the US. More work is needed to investigate the possible reasons for these differences. Policymakers should consider broadening policies allowing facilities to offer telehealth across state lines to improve telehealth wait times.

Figure 2. State-Specific Proportions of Surveyed Mental Health Treatment Facilities
With Reported Telehealth Services

Conclusion:

The COVID-19 pandemic has undeniably accelerated the shift towards telehealth in mental health care. However, prospective clients may face several hurdles in finding a facility that offers comprehensive telehealth services. Therefore, it is paramount to continue exploring ways to optimise the availability and accessibility of these services.

Reference url

Recent Posts

Shingles vaccine affordability
Shingles Vaccine Affordability and Its Impact on Public Health in South Africa

By João L. Carapinha

July 2, 2026

Shingles vaccine affordability remains a pressing concern as the recombinant zoster vaccine launches in South Africa. This vaccine delivers substantially higher efficacy and longer protection against herpes zoster and post-herpetic neuralgia than the live attenuated version withdrawn in 2024, yet...
health innovation access
Widespread Barriers to Health Innovation Access in Portugal

By João L. Carapinha

July 2, 2026

Health innovation access in Portugal is widely viewed as inadequate, with 80% of patient associations rating it as reasonable or poor. Only 14% say most relevant innovations reach patients without significant restrictions, according to a Medjournal.pt investigation. The gaps are most acute in ...
Retracted Trial Publication
Retracted Trial Publication Undermines Support for Avacopan in AAV Treatment

By João L. Carapinha

July 1, 2026

The Retracted Trial Publication of the ADVOCATE study has eliminated the central evidence that supported approval of Tavneos (avacopan) for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). At the request of two lead academic authors, the